Previous Article | Next Article ![]()
Molecular and Cellular Biology, August 2005, p. 6355-6362, Vol. 25, No. 15
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.15.6355-6362.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Nicholas J. Slater,1
C. Glenn Begley,2
Jessica M. Salmon,1
Leonie J. Van Stekelenburg,1
Matthew P. McCormack,1
Stephen M. Jane,1 and
David J. Curtis1*
Rotary Bone Marrow Research Laboratories, P.O. Box Royal Melbourne Hospital, Grattan St., Melbourne 3050, Australia,1 Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-17992
Received 20 December 2004/ Returned for modification 5 February 2005/ Accepted 8 May 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The stem cell leukemia gene (SCL) encodes a basic helix-loop-helix (bHLH) protein first cloned from a leukemic translocation (3). SCL is critical for the formation of primitive erythropoiesis in embryonic development (25, 27, 28, 31). In adult hematopoiesis, SCL is also believed to be essential for erythropoiesis. SCL is expressed in erythroid progenitors and maintained throughout erythroid development, with levels peaking at the CFU-E stage (4). Enforced expression of SCL favored erythroid proliferation and differentiation in cell lines and primary hematopoietic progenitors (7, 33). Continued expression of SCL in erythroid cells appears to be essential for erythropoiesis, as an SCL transgene expressed in hematopoietic progenitors but not erythroid cells failed to rescue erythropoiesis in SCL knockout embryos (30). More recently, analyses of conditional SCL knockout mice have supported the hypothesis that SCL is critical for adult erythropoiesis. Immediately after loss of SCL expression, in vitro and in vivo growth of erythroid progenitors was absent (8, 20). Furthermore, competitive transplant assays suggested that SCL was essential for mature red blood cell formation with a block in maturation at the CD71pos TER119low proerythroblast stage (5, 20). Thus, analyses of SCL-conditional knockout mice suggest that SCL is essential for maturation beyond the proerythroblast stage.
Within erythroid cells, SCL was identified within large protein complexes comprising not only its E-protein partner, but also LMO2, Lbd-1, GATA-1, pRb, and Sp1 (15, 36, 38). This SCL complex regulates transcription at promoters containing E-box GATA motifs and has been reported to positively and negatively modulate expression of target genes. Proposed erythroid target genes of this complex include the gene encoding the receptor for stem cell factor c-kit and the red blood cell membrane proteins glycophorin A and protein 4.2 (12, 14, 15, 41). Other potential erythroid targets of SCL include GATA-1 and EKLF, a transcription factor essential for expression of adult globin (1, 37). Thus, SCL is predicted to regulate erythroid commitment, proliferation, and maturation.
In this study, we have examined the long-term consequences for erythropoiesis of deleting SCL by using conditional SCL knockout mice. In light of the absence of BFU-E and a block in differentiation at the proerythroblast stage in SCL-deleted mice, we predicted that SCL would be essential for the production of mature red blood cells (5, 8, 20). Surprisingly, we found that SCL was important but not essential for continuing adult erythropoiesis, including a response to erythropoietic stress. This unexpected finding suggests that unlike in development, alternate factors or pathways can replace the essential functions of SCL in adult erythropoiesis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
) and control (SCL+/
)mice, respectively. All analyses were performed at least 4 weeks after administration of poly(I:C). Deletion of the SCLloxP allele was determined by Southern blotting by using an SCL probe that distinguished loxP,
, wild-type, and null SCL alleles (8). Peripheral blood analysis. For whole-blood counts, 250 µl of blood was collected from the retro-orbital plexus into tubes containing potassium EDTA (Sarstedt, Nümbrecht, Germany), and blood counts were analyzed with an Avidia 120 automated hematological analyzer (Bayer, Tarrytown, NY). Serum bilirubin was measured using the modified Pearlman and Lee method. Serum lactate dehydrogenase was measured by a photometric UV method. Red blood cell survival was measured by using direct in vivo biotinylation of erythrocytes (9). To induce erythropoiesis, mice were either given a single i.p. injection of darbepoetin (30 µg/kg of body weight; Amgen, Inc., Thousand Oaks, CA) or two i.p. injections of phenylhydrazine (60 mg/kg; Sigma) on consecutive days.
Flow cytometry and sorting.
For reticulocyte analysis and expression of TER119 on peripheral blood red blood cells, 5-µl aliquots of blood were incubated in 1 ml of thiazole orange (1 µg/ml; Sigma) and a saturating concentration of TER119-PE (BD Pharmingen, San Diego, CA) for 30 min in the dark and then analyzed with a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA). For analyses of red blood cell maturation, single-cell suspensions of bone marrow were stained with saturating concentrations of CD71-fluorescein isothiocyanate (FITC); TER119-PE; biotinylated nonerythroid lineage markers Mac-1
, B220, CD3 and Gr-1; and streptavidin-allophycocyanin conjugate (BD Pharmingen, San Diego, CA). Apoptosis of erythroid subpopulations were analyzed by costaining with annexin V-FITC (BD Pharmingen) and 7-AAD (Sigma). Immature cell populations were identified using CD34-FITC, CD16/CD32-PE, and biotinylated lineage markers including TER119, biotinylated interleukin 7 (IL-7) receptor
-chain, biotinylated Sca-1, and c-kit-allophycocyanin. Biotinylated antibodies were recognized with streptavidin-peridinin chlorophyll protein, and samples were analyzed with an LSR flow cytometer (BD Biosciences). Cells for Southern and gene expression analyses were sorted with a FACSVantage SE system (BD Biosciences); after sorting, cell purity of >90% was confirmed.
Real-time PCR. Real-time PCR analysis of gene expression was conducted using a Rotorgene 2000 instrument (Corbett Research, Sydney). Amplification of cDNA products was followed using the fluorescent DNA-binding dye SybrGreen (Molecular Probes, Oregon) at a dilution of 1:10,000. Gene expression of erythroid genes was normalized to expression of hypoxanthine phosphoribosyltransferase, and data are expressed as a percentage of the wild type. Gene-specific primer sequences are available on request.
BFU-E and CFU-E assays. Single-cell suspensions of bone marrow and spleen were plated in 0.9% methylcellulose, 20% fetal calf serum, Iscove's modified Dulbecco medium plus either 10 ng/ml murine interleukin 3 (R&D Systems, Minneapolis, MN), 50 ng/ml rat stem cell factor (Amgen, Inc.), and 4 U/ml human EPO (Amgen, Inc.) (for BFU-Es) or 4 U/ml EPO alone (for CFU-Es). Colonies were scored at day 7 for BFU-Es and day 2 for CFU-Es with an inverted phase-contrast microscope. Plates were stained with a solution of diaminobenzidine and hydrogen peroxide to confirm erythroid lineage.
In vivo assays. Bone marrow recipients were lethally irradiated with 2 doses of 550 rad administered 3 h apart from a 60Co gamma source at a dose rate of 45 rad/min 2 to 4 h before transplantation. Bone marrow cells for transplant were harvested by flushing femurs and tibias with phosphate-buffered saline-5% fetal bovine serum using a 21-gauge needle. Viability of single-cell suspensions was checked by trypan blue exclusion. The CFU-S assay was performed by injection of 3 x 104 bone marrow cells per recipient, and spleen colonies were analyzed on day 12. For competitive repopulation assays, age- and sex-matched B6-Hbbd (Ptprca [Ly5.1]) congenic mice were used as a source of competitor marrow cells and as recipients. Mice used as a source of competitor cells were not exposed to poly(I:C). Transplanted mice were fed antibiotic-treated water and maintained in hooded cages for the first 4 weeks. A minimum of three recipients were used for each donor cell population. The total donor cell dose was 2 x 106 cells. Hemoglobin electrophoresis was used to determine the donor erythroid contribution (40).
| RESULTS |
|---|
|
|
|---|
) remained alive for >6 months after loss of SCL expression, with only mild anemia and thrombocytopenia (Fig. 1A). White blood cell number was not affected by loss of SCL.
|
), indicating that most erythroblasts were truly SCL deleted (Fig. 1C). FACS-purified CD71neg TER119pos normoblasts also had an SCL-deleted genotype, showing that erythroid maturation was not blocked at an early stage (data not shown), as previously suggested (20). Finally, quantitative real-time PCR of whole bone marrow (Fig. 1D) and spleen cells (data not shown) from SCL-deleted mice demonstrated no detectable SCL mRNA. The absence of SCL mRNA despite the presence of nondeleted cells (Fig. 1B) is most likely explained by failure of the MxCre transgene to excise the SCL-targeted locus in cell types, such as stromal cells or lymphocytes, which do not express SCL. Together, these results demonstrated that SCL was not required for ongoing adult erythropoiesis. Although SCL was not essential for adult erythropoiesis, SCL was required for normal erythropoiesis: SCL-deleted mice were anemic with enlarged spleens (175 ± 60 mg compared with 109 ± 29 mg in controls; 24 mice) containing sixfold more erythroblasts (Fig. 1E). While red blood cell number and hemoglobin were reduced, red blood cell size and hemoglobin content were normal, suggesting that iron metabolism and globin production were not impaired (Table 1). There was also no evidence of a significant hemolytic component to the anemia: the reticulocyte percentage and serum bilirubin and lactate dehydrogenase levels were not significantly elevated in SCL-deleted animals (Table 1). Furthermore, red blood cell survival assayed by in vivo biotinylation was not significantly reduced in SCL-deleted mice (Table 1). From these analyses, defects in iron metabolism, globin production, or the red blood cell membrane are unlikely to be a significant contributors to the anemia observed with SCL-deleted mice.
|
|
|
Abnormal in vitro growth of SCL-deleted erythroid progenitors.
Despite ongoing erythropoiesis in SCL-deleted mice that was sufficient to maintain a near normal hematocrit and respond to erythroid stress, the in vitro progenitor growth from SCL-deleted bone marrow and spleen was markedly abnormal. While the numbers and size of CFU-Es were normal, cultures stimulated with IL-3, SCF, and EPO did not generate detectable BFU-Es (Fig. 4A). Supramaximal concentrations of cytokines, addition of dexamethasone, and culture on primary marrow stroma all failed to support erythroid colony growth from SCL-deleted bone marrow and spleen cells (data not shown). BFU-Es were also absent following erythroid stress. CFU-Es following phenylhydrazine-induced hemolysis increased in number compared with the steady state but were two- to fourfold smaller than CFU-Es from control mice (Fig. 4B). While it is impossible to enumerate BFU-Es other than by in vitro growth assays, the immediate precursor of the BFU-E, the common MEP, can be identified in the bone marrow by its characteristic cell surface phenotype, Lin Sca-1 IL-7R
c-kit+ Fc
Rlow CD34 (22). Examination of SCL-deleted bone marrow cells by flow cytometry revealed a threefold increase in the number of MEP cells (Fig. 4C). In contrast, the numbers of common myeloid and granulocyte-macrophage progenitors were unaltered. Sorted MEP cells from SCL-deleted mice cultured in IL-3, SCF, and EPO did not generate BFU-Es or CFU-Es (data not shown). Thus, cells with the characteristic MEP phenotype were increased in the SCL-deleted mice but, like BFU-E, did not generate erythroid cells in standard in vitro growth conditions.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Although the erythroid compartment functioned adequately, SCL is still required for normal erythropoiesis because mice are moderately anemic. Characteristics of the red blood cell parameters, including markers of hemolysis, suggest that increased red blood cell destruction is not a major contributor to the anemia. In contrast, the small size of SCL-deleted CFU-S12 cells in the absence of significant apoptosis and the competitive disadvantage of SCL-deleted erythropoiesis support the conclusion that the anemia is predominantly due to a defect in erythroid proliferation. The absence of BFU-E suggests that SCL acts at the level of immature erythroid progenitors, which can be overcome iby some as-yet-undefined mechanism in vivo. We do not believe that the BFU-Es are bypassed directly to the CFU-Es in vivo because FACS-isolated MEP cells did not form CFU-Es (data not shown). The relative preservation of the CFU-E is consistent with the ability of SCL-deleted mice to respond to erythroid stress, which is mediated predominantly by expansion of CFU-Es (19). Expression of an SCL DNA-binding mutant in CD34+ cells suggested that SCL DNA binding was important for proliferation of early erythroid progenitors (BFU-E) but not the more mature CFU-E (26). Consistent with defects in DNA binding, SCL-deleted red blood cells have reduced expression of TER119. Although the antigen recognized by TER119 antisera has not been cloned, evidence suggests that it is glycophorin A (2, 10), a recently proposed DNA-binding target gene of SCL (14).
Redundancy in mouse knockouts is usually explained by the presence of a functionally related gene. For example, normal platelet production in GATA-1 knockout cells has been attributed to coexpression of GATA-2 in megakaryocytes (23). In the case of SCL, it seems likely that another bHLH factor may be replacing many of the functions of SCL in hematopoiesis. The most likely candidate is Lyl-1 because the bHLH domain of Lyl-1 rescued the hematopoiesis of SCL/ ES cells (24). Lyl-1 is expressed in cell types similar to SCL and has dimerization properties similar to those of SCL (17, 35) In addition, the predicted DNA-binding preference for Lyl-1-E2a heterodimers was almost identical to that of SCL-E2a heterodimers (21).
It has been proposed that SCL belongs to a class of transcription factors required for the formation of hematopoietic stem cells, but once formed, SCL is no longer required for hematopoietic stem cell activity (20). Similarly, it is possible that SCL is also not required for erythropoiesis once erythroid progenitors are formed. More likely, alternate factors such as Lyl-1 could replace the function of SCL in erythropoiesis. If correct, then expression of Lyl-1 or another bHLH may also explain the lack of a major stem cell defect in the SCL-deleted mice.
There are several possible explanations for the critical role of SCL in the developing embryo yet the relative redundancy in the adult. First, it is likely that SCL has unique target genes critical for hematopoietic specification. Second, the factors involved in the establishment of the SCL-independent erythroid program in the adult may not be expressed in the required spatiotemporal fashion in the developing embryo. The expression pattern of Lyl-1 in development has not been examined in detail but may differ significantly from SCL. Third, SCL-independent erythropoiesis can occur in the embryo but is insufficient to allow survival of the embryo. The concept that adult hematopoiesis is more resilient than embryonic development to loss of gene function is supported by the phenotype of GATA-1 knockdown mutations (16). The majority of GATA-1lo mice die during embryogenesis, but in the small proportion of mice that survive to adulthood, their hematocrit levels and ability to response to erythroid stress return to normal in the first few weeks of life (34). The recovery of erythropoiesis in adult GATA-1lo mice has been attributed to selection of clones the expressing GATA-1 at the highest levels; however, this cannot explain the recovery of erythropoiesis in SCL-conditional knockout mice. Our demonstration that SCL was not essential for erythropoiesis provides a rationale for generating conditional knockouts of other transcription factors, such as GATA-1, also believed to be essential for adult erythropoiesis.
In summary, contrary to previous claims, our analyses of SCL conditional knockout mice demonstrate that erythropoiesis can occur in the absence of SCL. This unexpected finding suggests that alternate factors or pathways can replace the essential erythropoietic functions of SCL in the adult but not the embryo. Identification of the mechanism of SCL-independent erythropoiesis in the adult will provide valuable insights into the transcriptional regulation of erythropoiesis.
| ACKNOWLEDGMENTS |
|---|
This work was supported in part by the NHMRC, Australia, and NIH grants PO1 HL53749-03 and RO1 HL69232-01.
| FOOTNOTES |
|---|
Present address: St. Jude Children's Research Hospital, Memphis, TN. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Auffray, I., S. Marfatia, K. de Jong, G. Lee, C. H. Huang, C. Paszty, M. J. Tanner, N. Mohandas, and J. A. Chasis. 2001. Glycophorin A dimerization and band 3 interaction during erythroid membrane biogenesis: in vivo studies in human glycophorin A transgenic mice. Blood 97:2872-2878.
3. Begley, C. G., P. D. Aplan, M. P. Davey, K. Nakahara, K. Tchorz, J. Kurtzberg, M. S. Hershfield, B. F. Haynes, D. I. Cohen, T. A. Waldmann, and I. R. Kirsch. 1989. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc. Natl. Acad. Sci. USA 86:2031-2035.
4. Condorelli, G., L. Vitelli, M. Valtieri, I. Marta, E. Montesoro, V. Lulli, R. Baer, and C. Peschle. 1995. Coordinate expression and developmental role of Id2 protein and TAL1/E2A heterodimer in erythroid progenitor differentiation. Blood 86:164-175.
5. Curtis, D. J., M. A. Hall, L. J. Van Stekelenburg, L. Robb, S. M. Jane, and C. G. Begley. 2004. SCL is required for normal function of short-term repopulating hematopoietic stem cells. Blood 103:3342-3348.
6. Elefanty, A. G., C. G. Begley, D. Metcalf, L. Barnett, F. Kontgen, and L. Robb. 1998. Characterization of hematopoietic progenitor cells that express the transcription factor SCL, using a lacZ "knock-in" strategy Proc. Natl. Acad. Sci. USA 95:11897-11902.
7. Elwood, N. J., H. Zogos, D. S. Pereira, J. E. Dick, and C. G. Begley. 1998. Enhanced megakaryocyte and erythroid development from normal human CD34(+) cells: consequence of enforced expression of SCL. Blood 91:3756-3765.
8. Hall, M. A., D. J. Curtis, D. Metcalf, A. G. Elefanty, K. Sourris, L. Robb, J. R. Gothert, S. M. Jane, and C. G. Begley. 2003. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc. Natl. Acad. Sci. USA 100:992-997.
9. Hoffmann-Fezer, G., H. Maschke, H. J. Zeitler, P. Gais, W. Heger, J. Ellwart, and S. Thierfelder. 1991. Direct in vivo biotinylation of erythrocytes as an assay for red cell survival studies. Ann. Hematol. 63:214-217.[CrossRef][Medline]
10. Kina, T., K. Ikuta, E. Takayama, K. Wada, A. S. Majumdar, I. L. Weissman, and Y. Katsura. 2000. The monoclonal antibody TER119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109:280-287.[CrossRef][Medline]
11. Krantz, S. B. 1991. Erythropoietin. Blood 77:419-434.
12. Krosl, G., G. He, M. Lefrancois, F. Charron, P. H. Romeo, P. Jolicoeur, I. R. Kirsch, M. Nemer, and T. Hoang. 1998. Transcription factor SCL is required for c-kit expression and c-Kit function in hemopoietic cells. J. Exp. Med. 188:439-450.
13. Kuhn, R., F. Schwenk, M. Aguet, and K. Rajewsky. 1995. Inducible gene targeting in mice. Science 269:1427-1429.
14. Lahlil, R., E. Lecuyer, S. Herblot, and T. Hoang. 2004. SCL assembles a multifactorial complex that determines glycophorin A expression. Mol. Cell. Biol. 24:1439-1452.
15. Lecuyer, E., S. Herblot, M. Saint-Denis, R. Martin, C. G. Begley, C. Porcher, S. H. Orkin, and T. Hoang. 2002. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood 100:2430-2440.
16. McDevitt, M. A., R. A. Shivdasani, Y. Fujiwara, H. Yang, and S. H. Orkin. 1997. A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc. Natl. Acad. Sci. USA 94:6781-6785.
17. Mellentin, J. D., S. D. Smith, and M. L. Cleary. 1989. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58:77-83.[CrossRef][Medline]
18. Metcalf, D. 1984. Haemopoietic colony-stimulating factors. Elsevier, Amsterdam, The Netherlands.
19. Mide, S. M., P. Huygens, C. E. Bozzini, and J. A. Fernandez Pol. 2001. Effects of human recombinant erythropoietin on differentiation and distribution of erythroid progenitor cells on murine medullary and splenic erythropoiesis during hypoxia and post-hypoxia. In Vivo 15:125-132.[Medline]
20. Mikkola, H. K., J. Klintman, H. Yang, H. Hock, T. M. Schlaeger, Y. Fujiwara, and S. H. Orkin. 2003. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 421:547-551.[CrossRef][Medline]
21. Miyamoto, A., X. Cui, L. Naumovski, and M. L. Cleary. 1996. Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells. Mol. Cell. Biol. 16:2394-2401.[Abstract]
22. Na Nakorn, T., D. Traver, I. L. Weissman, and K. Akashi. 2002. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J. Clin. Investig. 109:1579-1585.[CrossRef][Medline]
23. Pevny, L., C. S. Lin, V. D'Agati, M. C. Simon, S. H. Orkin, and F. Costantini. 1995. Development of hematopoietic cells lacking transcription factor GATA-1. Development 121:163-172.[Abstract]
24. Porcher, C., E. C. Liao, Y. Fujiwara, L. I. Zon, and S. H. Orkin. 1999. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development 126:4603-4615.[Abstract]
25. Porcher, C., W. Swat, K. Rockwell, Y. Fujiwara, F. W. Alt, and S. H. Orkin. 1996. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages Cell 86:47-57.[CrossRef][Medline]
26. Ravet, E., D. Reynaud, M. Titeux, B. Izac, S. Fichelson, P. H. Romeo, A. Dubart-Kupperschmitt, and F. Pflumio. 2004. Characterization of DNA-binding-dependent and -independent functions of SCL/TAL1 during human erythropoiesis. Blood 103:3326-3335.
27. Robb, L., N. J. Elwood, A. G. Elefanty, F. Kontgen, R. Li, L. D. Barnett, and C. G. Begley. 1996. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 15:4123-4129.[Medline]
28. Robb, L., I. Lyons, R. Li, L. Hartley, F. Kontgen, R. P. Harvey, D. Metcalf, and C. G. Begley. 1995. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc. Natl. Acad. Sci. USA 92:7075-7079.
29. Robertson, S. M., M. Kennedy, J. M. Shannon, and G. Keller. 2000. A transitional stage in the commitment of mesoderm to hematopoiesis requiring the transcription factor SCL/tal-1. Development 127:2447-2459.[Abstract]
30. Sanchez, M. J., E. O. Bockamp, J. Miller, L. Gambardella, and A. R. Green. 2001. Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development 128:4815-4827.
31. Shivdasani, R. A., E. L. Mayer, and S. H. Orkin. 1995. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 373:432-434.[CrossRef][Medline]
32. Socolovsky, M., H. Nam, M. D. Fleming, V. H. Haase, C. Brugnara, and H. F. Lodish. 2001. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98:3261-3273.
33. Valtieri, M., A. Tocci, M. Gabbianelli, L. Luchetti, B. Masella, L. Vitelli, R. Botta, U. Testa, G. L. Condorelli, and C. Peschle. 1998. Enforced TAL-1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program. Cancer Res. 58:562-569.
34. Vannucchi, A. M., L. Bianchi, C. Cellai, F. Paoletti, V. Carrai, A. Calzolari, L. Centurione, R. Lorenzini, C. Carta, E. Alfani, M. Sanchez, G. Migliaccio, and A. R. Migliaccio. 2001. Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression. Blood 97:3040-3050.
35. Visvader, J., C. G. Begley, and J. M. Adams. 1991. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene 6:187-194.[Medline]
36. Vitelli, L., G. Condorelli, V. Lulli, T. Hoang, L. Luchetti, C. M. Croce, and C. Peschle. 2000. A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts. Mol. Cell. Biol. 20:5330-5342.
37. Vyas, P., M. A. McDevitt, A. B. Cantor, S. G. Katz, Y. Fujiwara, and S. H. Orkin. 1999. Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. Development 126:2799-2811.[Abstract]
38. Wadman, I. A., H. Osada, G. G. Grutz, A. D. Agulnick, H. Westphal, A. Forster, and T. H. Rabbitts. 1997. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 16:3145-3157.[CrossRef][Medline]
39. Wessely, O., E. M. Deiner, H. Beug, and M. von Lindern. 1997. The glucocorticoid receptor is a key regulator of the decision between self-renewal and differentiation in erythroid progenitors. EMBO J. 16:267-280.[CrossRef][Medline]
40. Whitney, J. B., III. 1978. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem. Genet. 16:667-672.[CrossRef][Medline]
41. Xu, Z., S. Huang, L. S. Chang, A. D. Agulnick, and S. J. Brandt. 2003. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. Mol. Cell. Biol. 23:7585-7599.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|